欧洲人甚至在未分化阶段就用mtx

可惜不是你

Early TreatmentResults of a study presented at the Annual European Congress of Rheumatology by Henrike Van Dongen, MD, Leiden University Medical Center, Netherlands, and her colleagues on June 21, 2006, suggests that people diagnosed with undifferentiated rheumatoid arthritis could have their disease outlook changed significantly if the proper treatment is given at the right time.

The PROMPT-study (Probable rheumatoid arthritis: Methotrexate versus Placebo Treatment-study), a double-blind, placebo controlled, randomized, multicenter trial in 110 participants with undifferentiated (having an undetermined diagnosis) rheumatoid arthritis (RA), was conducted to determine whether participants would benefit from treatment with methotrexate.

The study concluded that the methotrexate group had fewer patients develop RA during the observed time and more participants reached remission than in the group receiving placebo. “This data is excellent news as it shows that methotrexate appears to delay or even prevent progression to rheumatoid arthritis amongst patients," said another member of the study Tom Huizinga, MD, Leiden University Medical Center, Netherlands.

Methotrexate is a disease modifying anti-rheumatic drug (DMARD) and is well established in the treatment of cancer and autoimmune diseases such as RA. In rheumatoid arthritis, methotrexate seems to work, in part, by altering aspects of immune function which may play a role in causing the disease.

“One of the most interesting findings from the study was that the patients who benefited the most were the ones showing a positive anti-CCP test, which would in general terms show that a patient has a very high likelihood to develop full-blown RA. However, this study indicates that the progression to a full-blown disease amongst these patients could be influenced,” noted Dr. Dongen.

"This is an important study," said John H. Klippel, MD, President and CEO, Arthritis Foundation, "which suggests that there may be a window very early in the development of rheumatoid arthritis in which treatment significantly alters the course of the disease. Identifying patients in this phase of the disease and instituting treatment is an important public health goal."

可惜不是你

这个研究提示在有一些症状时, 就用mtx, 甚至可以阻止RA的发生

看来早期诊断的意义重大

宅姨

查了下手头的专业书,关键是未分化的ra(UA)如何判断,学术上还有争议.所以,似乎MTX早期介入真是两难.万一不是ra呢?

可惜不是你

文中的意思应该是, 有一些症状, 但是没有确诊的

可惜不是你

3# 宅姨

万一不是,mtx的负作用也不至于引起严重的后果吧

110例的双盲试验能说明一些问题

宅姨

恩，也许。我住院时的同屋，住院时怀疑反应性关节炎，因为她感冒了，然后就全身疼，尤其四肢和脚腕。类风湿因子稍微高一点，其他免疫指标都正常。后来还是定了类风湿。只吃4片/周MTX。我查了，即使是反应性关节炎，也可以用MTX。

散木

写的啥呀？可惜不是你，请翻译一下，好吗？

宅姨

写的啥呀？可惜不是你，请翻译一下，好吗？
散木 发表于 2010-10-27 16:16

[xiao] 我差点笑出声来，就是。

可惜不是你

大概说:

110个有症状, 没确诊的分2组

一组给mtx, 一组给安慰剂

对比发现早期用mtx的, 会更慢的演变成ra甚至可能由于用mtx, 本来可能发展成ra的,并没有发展

另外,ccp高的更可能发展成典型的ra

宅姨

我试着简单翻译下帖子的内容吧。这不是新闻了。在2006年6月21日，荷兰Leidon大学的女学者和她的研究小组，提交了一份报告。就是对110名未分化的ra患者做了一项试验。报告指出，早期介入MTX，可以推迟或者避免这些患者得上明确的ra。这个报告也得到了国际风湿病联合会的主席的肯定，因为它对公共健康有贡献。还是请楼主翻得更准确些吧。